Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | MLYCD | O95822 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MMP8 | P22894 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3833319 | 0.89 | MLYCD (0.62) | POLBMLYCDNPC1RAB9AMMP8 | |
| SCHEMBL3135827 | 0.87 | POLB (0.56) | POLBMLYCDL3MBTL1NPC1RAB9A | |
| SCHEMBL3135061 | 0.86 | POLB (0.55) | POLBMLYCDL3MBTL1NPC1RAB9A | |
| SCHEMBL8699335 | 0.85 | POLB (0.55) | POLBMLYCDHPGDKMT2AKDM4E | |
| SCHEMBL4459001 | 0.83 | POLB (0.53) | POLBMLYCDL3MBTL1NPC1RAB9A | |
| SCHEMBL16935825 | 0.83 | POLB (0.53) | POLBMLYCDL3MBTL1NPC1RAB9A | |
| SCHEMBL2549950 | 0.83 | POLB (0.53) | POLBMLYCDNPC1HPGDMMP8 | |
| SCHEMBL5071492 | 0.83 | POLB (0.53) | POLBMLYCDL3MBTL1KMT2ACYP2D6 | |
| SCHEMBL1710649 | 0.83 | POLB (0.51) | POLBMLYCDL3MBTL1NPC1RAB9A | |
| SCHEMBL12356333 | 0.83 | POLB (1.00) | POLBL3MBTL1NPC1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3096751-B1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-01-06 | — | — | EP | disclosed |
| CN-105916499-B | 12-epi-pleuromutilins | 纳布里瓦治疗股份公司 | 2020-02-18 | — | — | CN | disclosed |
| US-9701628-B2 | 12-epi pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2017-07-11 | — | — | US | disclosed |
| US-20170057964-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2017-03-02 | — | — | US | disclosed |
| EP-3096751-A1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics AG (AT) | 2016-11-30 | — | — | EP | disclosed |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2016-11-17 | — | — | US | disclosed |
| US-20160024093-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2015110481-A1 | 12-EPI-PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2015-07-30 | — | — | WO | disclosed |
| US-8969565-B2 | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130245021-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2013-09-19 | — | — | US | disclosed |
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |
| WO-2003104266-A2 | PEPTIDES AND PEPTIDOMIMETICS USEFUL FOR INHIBITING THE ACTIVITY OF PROSTAGLANDIN F2α RECEPTOR | THERATECHNOLOGIES INC. (CA) | 2003-12-18 | — | — | WO | disclosed |
| US-6245746-B1 | ADMINISTERING AMIDE MICROBIOCIDE ANTIBIOTIC | MICROCIDE PHARMACEUTICALS, INC. | 2001-06-12 | — | — | US | disclosed |
| US-6235731-B1 | REDUCING BLOOD LIPIDS, SUGARS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| US-6114310-A | THERAPY FOR MICROBIAL INFECTIONS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| WO-1999037667-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| CN-1223659-A | Fused imidazopyridine derivatives as antihyperlipidemic agents | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-07-21 | — | — | CN | disclosed |
| EP-0915888-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | Takeda Chemical Industries, Ltd. (JP) | 1999-05-19 | — | — | EP | disclosed |
| WO-1997040051-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024093-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | IRAK2, IRAK1, GRB2 | POLB 2808/4885MLYCD 2656/4885L3MBTL1 1155/4885 |
| US-20170057964-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | IRAK2, IRAK1, GRB2 | POLB 2808/4885MLYCD 2656/4885L3MBTL1 1155/4885 |
| US-20130245021-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | IRAK2, IRAK1, GRB2 | POLB 2808/4885MLYCD 2656/4885L3MBTL1 1155/4885 |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | MLN, TCF12, PLEC | POLB 814/4885MLYCD 3845/4885L3MBTL1 1445/4885 |
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | POLB 972/4885MLYCD 2946/4885L3MBTL1 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.